hotspot -WSS

hotspot

author：hotspot 2025-09-28 16:35:20 - browse：1

Illumina said Monday afternoon that its board of directors had approved a spin-off of its cancer test subsidiary Grail, signaling that a nearly four-year-long, $8 billion saga will finally draw to a close this month.

Shares in the newly independent Grail are expected to be distributed on June 24, Illumina said in a statement. Illumina will retain a 14.5% stake in the company, which will trade under the ticker $GRAL.

It’s the second time Illumina has spun off Grail, which initially began as a unit within the DNA sequencing giant in 2015. Illumina turned it into an independent company the following year but then agreed to reacquire it for $8 billion in September 2020.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： NIH documents show early flaws of $1.6 billion long Covid program

WSS

Key Senate committee drafts bipartisan bill to stem drug shortages

ASCO: Palliative care found as helpful given virtually as in person

H5N1 bird flu found in pasteurized milk: what we know

ASCO: Palliative care found as helpful given virtually as in person

Exact Sciences stock tumbles despite strong cancer detection sales

ASCO: Palliative care found as helpful given virtually as in person

entertainment

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

23andMe had bad news about my health. I wish a person had delivered it

At ASCO, AstraZeneca reports strong data for breast cancer drug

Medicare details structure of new drug price negotiation program

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Moonlake's readout produced a cash windfall. Risks remain

More tobacco lobbyists active in statehouses

Virginia high school admissions case could be legal follow

UnitedHealth financials solid despite Change Healthcare cyberattack

Jerome Adams on the need for new antivirals for Covid

BMI, flaws aside, is found to be useful estimate of body fat in youth

focus

Cholera vaccine supply gets boost as demand surges globally

Cancer researcher Catriona Jamieson is sending tumors into space

HIV drugs protect against transmission, even in unprotected sex

Exact Sciences stock tumbles despite strong cancer detection sales

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Why does health care cost so much? A reading guide

leisure time

hotspot

focus

focus